Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 Biomarker disease BEFREE ALK- ALCL lacks ALK protein expression, but expresses CD30 and has morphologic features similar to ALK positive anaplastic large cell lymphoma (ALK+ ALCL). 31072226 2019
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 Biomarker disease BEFREE We have previously shown that treatment of ALK-positive anaplastic large cell lymphoma cells with the ALK tyrosine kinase inhibitor crizotinib induces autophagy as a pro-survival response. 30679328 2019
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 Biomarker disease BEFREE NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma. 31428523 2019
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 Biomarker disease BEFREE Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma. 29642597 2018
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 Biomarker disease BEFREE To illustrate and study cancer cell plasticity in hematopoietic cancers, we employed an in-vitro experimental model of ALK-positive anaplastic large-cell lymphoma (ALK+ALCL) that is based on the phenotypic and functional dichotomy of these cells, with cells responsive to a Sox2 reporter (i.e. 29609590 2018
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 AlteredExpression disease BEFREE Here, we describe a novel truncated form of the ALK transcript with in-frame skipping through exons 2 to 17 (ALKΔ2-17) in anaplastic large cell lymphoma, ALK-positive. 28665006 2018
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 GeneticVariation disease BEFREE Over the last few years, studies have demonstrated the occurrence of autophagy in different Anaplastic Lymphoma Kinase (ALK)-associated cancers, notably ALK-positive anaplastic large cell lymphoma (ALCL), non-small cell lung carcinoma (NSCLC), Neuroblastoma (NB), and Rhabdomyosarcoma (RMS). 29186933 2017
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 Biomarker disease BEFREE Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma. 26133723 2016
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 Biomarker disease BEFREE Cellular immune responses against the oncoantigen anaplastic lymphoma kinase (ALK) in patients with ALK-positive anaplastic large cell lymphoma (ALCL) have been detected using peptide-based approaches in individuals preselected for human leucocyte antigen (HLA)-A*02:01. 27414060 2016
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 Biomarker disease BEFREE STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma. 25921060 2015
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 Biomarker disease BEFREE First, the 'anaplastic large cell lymphoma, ALK positive' (ALK(+) ALCL) that is characterized by the presence of ALK gene rearrangements and consequent ALK protein expression, and, second, the 'anaplastic large cell lymphoma, ALK negative' (ALK(-) ALCL) that is a provisional entity lacking ALK protein expression but cannot be distinguished morphologically from ALK(+) ALCL. 25559471 2015
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 Biomarker disease BEFREE Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. 24509625 2014
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 AlteredExpression disease BEFREE Since the discovery of ALK-positive anaplastic large-cell lymphoma in 1994 many other types of tumors showing ALK expression were disclosed. 24490615 2014
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 Biomarker disease BEFREE We studied the prognostic value of minimal disseminated disease (MDD) and anti-ALK immune response in children with NPM-ALK-positive anaplastic-large cell lymphoma (ALCL) and evaluated their potential for risk stratification. 22907048 2013
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 Biomarker disease BEFREE Identification of a novel crosstalk between casein kinase 2α and NPM-ALK in ALK-positive anaplastic large cell lymphoma. 23153582 2013
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 Biomarker disease BEFREE It induced concentration-dependent growth inhibition/cytotoxicity of ALK-positive anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells, and displayed dose-dependent inhibition of ALK tyrosine phosphorylation in tumor xenografts in mice, with substantial target inhibition (>90%) for more than 12 hours following single oral dosing at 30 mg/kg. 22203728 2012
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 AlteredExpression disease BEFREE While the expression of SALL4 is normally restricted to ESCs and somatic stem cells, we found that it is aberrantly expressed in ALK-positive anaplastic large cell lymphoma (ALK+ ALCL), a type of lymphoid malignancy carrying a mature T-cell immunophenotype. shRNA knockdown of SALL4 in ALK+ ALCL cell lines resulted in apoptosis and cell-cycle arrest, and significantly decreased colony formation on soft agar. 22743134 2012
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 Biomarker disease BEFREE I propose that tumors carrying abnormal ALK as an essential growth driver be collectively termed "ALKoma." 22614325 2012
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 Biomarker disease BEFREE The fusion tyrosine kinase NPM-ALK is central to the pathogenesis of ALK-positive anaplastic large cell lymphoma (ALK(+)ALCL). 21703420 2011
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 GeneticVariation disease BEFREE With the exception of ALK-positive anaplastic large cell lymphoma (ALCL), which is defined on the basis of ALK rearrangements, genetic features play little role in the definition of other disease entities. 22160055 2011
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 GeneticVariation disease BEFREE ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) is an uncommon non-Hodgkin's lymphoma of T-cell origin, the majority of which express CD4 and show frequent pan-T-cell antigen loss. 21763080 2011
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 GeneticVariation disease BEFREE Although a few cases of ALK-positive large B-cell lymphoma harbor nucleophosmin-ALK chromosomal translocation similar to ALK-positive anaplastic large cell lymphoma, most reported cases are characterized by t(2;17)(p23;q23) involving the clathrin gene. 18755494 2009
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 Biomarker disease BEFREE Overexpression of c-myc has been shown to be a consistent finding in ALK+, but not ALK-negative ALCL (ALK- ALCL), and the c-myc gene is considered a downstream target of deregulated ALK signaling. 16955462 2007
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 AlteredExpression disease BEFREE Prognostic significance of NPM-ALK fusion transcript overexpression in ALK-positive anaplastic large-cell lymphoma. 17464320 2007
Anaplastic Large Cell Lymphoma, ALK-Positive
0.400 AlteredExpression disease BEFREE NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma. 16709933 2006